Drugs / BEA 2180 BR
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02254109 | Apr → Oct 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02258971 | Mar → May 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02254135 | Dec 2006 → Jan 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02254720 | Sep → Dec 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02254122 | May 2004 → Feb 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02263976 | Aug 2003 → Jun 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT00528996 | Sep 2007 → May 2009 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | Met primary |
| Phase 2 | NCT00128440 | Aug 2005 → Sep 2006 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00122434 | Jul 2005 → May 2006 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02242279 | Jun → Dec 2004 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEA 2180 BR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02254135 ↗ |
| Known as | BEA2180 | “To determine the safety and efficacy of BEA2180, an anticholinergic agent in patients with chronic obstructive pulmonary disease (COPD).” PMID 23490224 ↗ Mar 2013 |
| Route | Inhaled | “BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler” NCT00122434 ↗ |